3.73 USD
▼-0.11-2.86%
盘后 3.90 +4.56%
2026-09-15
市值
$371.13M
市盈率
—
EPS
-0.43
股息率
—
52 周区间
2.03 – 7.13
成交量
327.23K
Beta
0.39
目标价
—
52W 低 2.0352W 高 7.13
价格走势
公司简介
Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in drug development to create new therapies for fibrotic disease and cancer. The company’s lead product candidate is belapectin (GR-MD-02), a galectin-3 inhibitor, which is in a Phase 2 clinical study in MASH patients with advanced fibrosis and a second Phase 2b clinical trial in MASH patients with compensated cirrhosis and portal hypertension. It has a joint venture co-owned by SBH Sciences, Inc. to research and develop small organic molecule inhibitors of galectin...